Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Silver dressing may soothe radiation burns in breast cancer patients

NCT ID NCT06831084

Symptom relief Sponsor: Parul Barry Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a silver-plated wound dressing (Silverlon) in 17 breast cancer patients receiving radiation therapy. The goal was to see if the dressing could reduce the severity of acute radiation dermatitis, a common skin reaction that causes redness, peeling, and pain. Patients wore the dressing during treatment and for two weeks after, and their skin was checked weekly and one month later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Silver-plated dressing (Silverlon)
What this could lead to
If it works, this could give breast cancer patients a simple way to reduce painful skin rashes during radiation therapy.
What could go wrong
This was a very small, early-phase trial with only 17 people and no comparison group, so results may not apply to everyone. The dressing may not prevent severe skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17 people

The number who actually took part.

Started

May 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ECOG ≤ 2 2. Male or female patients with breast cancer or breast carcinoma in situ who are recommended to receive adjuvant radiotherapy to the breast +/- regional lymph nodes or are planned to receive adjuvant radiotherapy to the chest wall and regional lymph nodes over 3 to 4 weeks. 3. Patients who will receive all of their RT at Magee Women's Hospital. 4. Agreeable to use of SPT dressing as directed (changing once weekly during RT and the additional 2 weeks following completion of RT). 5. Agreeable that any normal or physician recommended skin care regimen is to be used 1 hour prior to use of SPT dressing. 6. Agreeable to completion of assessments and skin checks and in person follow up at about 1 month following completion of RT. 7. Must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Prior RT to the breast +/- regional lymph nodes or prior RT to the chest wall and regional lymph nodes. 2. Contraindication to the application of SPT dressing (e.g. allergy). 3. Pregnancy/lactation or women of childbearing potential who are unable or unwilling to use adequate contraception during RT. 4. Planned RT course \>4 weeks or \<3 weeks. 5. Active connective tissue disorders/collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash in the area that will receive RT, systemic lupus erythematosis, or scleroderma. 6. Medical, psychiatric or other condition that would prevent the patient from receiving the protocol therapy or providing informed consent. 7. Known sensitivity or allergy to silver or nylon.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma in situ radiodermatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radiation dermatitis acute

Contacts and locations

Locations

  • UPMC Magee-Womens Hospital

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.